AbbVie spent billions of dollars to acquire a potential cancer drug known as Rova-T, but the drug is looking more and more like a bad investment, Business Insider reports.
Details: AbbVie has stopped enrolling new patients in a Phase 3 clinical trial for Rova-T, which an outside monitoring committee had recommended. The drug was intended to treat advanced lung cancer. But in the clinical trial, patients taking Rova-T were dying sooner than patients treated with standard chemotherapy, per BI.
Illustration: Sarah Grillo/Axios
Photo: Doug Mills-Pool/Getty Images
Joe Biden leads President Trump 48% to 42% in Wisconsin and 49% to 43% in Pennsylvania, according to the latest CBS/YouGov Battleground Tracker poll.
Why it matters: Trump's surprise wins in the two states, where many voters broke his way after deciding the week before the election, helped propel him to an Electoral College victory over Hillary Clinton. Trump won Wisconsin with 47% of the vote and Pennsylvania with 48% in 2016, according to the New York Times.
Sen. Richard Blumenthal (D- Conn.) called on the Trump administration to declassify intelligence detailing Russian efforts to influence the 2020 elections, telling MSNBC on Sunday that the classified briefing lawmakers received about the Kremlin's activities last week was "absolutely chilling."
The big picture: National Counterintelligence and Security Center Director William Evanina said in a statement Friday that the Russian government is "using a range of measures" to "denigrate" Joe Biden ahead of the election. China and Iran would prefer that Trump is defeated, according to Evanina.